FDA cleared LTZ’s IND application for a second asset, LTZ-232, to treat patients with advanced metastatic colorectal cancer and other solid tumors. This regulatory milestone adds new clinical optionality beyond the first program and should be viewed as a near-term positive for LTZ’s pipeline.
FDA cleared LTZ’s IND application for a second asset, LTZ-232, to treat patients with advanced metastatic colorectal cancer and other solid tumors. This regulatory milestone adds new clinical optionality beyond the first program and should be viewed as a near-term positive for LTZ’s pipeline.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.45
